@article{JGO17065,
author = {Brice Jabo and Matthew J. Selleck and John W. Morgan and Sharon S. Lum and Khaled A. Bahjri and Mayada Aljehani and Carlos A. Garberoglio and Mark E. Reeves and Jukes P. Namm and Naveenraj L. Solomon and Fabrizio Luca and Crickett Dyke and Maheswari Senthil},
title = {Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {1},
year = {2017},
keywords = {},
abstract = {Background: Both perioperative chemotherapy (PC) and adjuvant chemoradiotherapy (CRT) improve survival in resectable gastric cancer; however, these treatments have never been formally compared. Our objective was to evaluate treatment trends and compare survival outcomes for gastric cancer patients treated with surgery and either PC or CRT.
Methods: We performed a retrospective population-based cohort study between 2007 through 2013 using California Cancer Registry data. Patients diagnosed with stage IB–III gastric adenocarcinoma and treated with total or partial gastrectomy were eligible for this study. Based on the type of treatment received, patients were grouped into surgery-only, PC, or CRT. Primary and secondary outcomes were overall survival (OS) and gastric cancer-specific survival (GCCS) respectively. Mortality hazards ratios (HRs) for each of these outcomes were computed using propensity score weighted and covariate-adjusted Cox regression models, stratified by clinical node status.
Results: Of 2,146 patients who underwent surgical resection, 1,067 had surgery-only, while 771 and 308 received PC or CRT, respectively. Median OS was 25, 33, and 52 months for surgery-only, PC, and CRT, respectively; P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/17065}
}